Scancell Holdings (GB:SCLP) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Scancell Holdings is set to raise at least £8.5 million through a new share placement and a director subscription, alongside a potential additional £1 million from a retail offer. This capital boost aims to support Scancell’s ongoing clinical trials and extend its cash runway, with promising early data from its cancer vaccine, SCIB1, showing significant patient responses. Investors in the biotech sector are likely to find this move an encouraging signal of future growth and innovation.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.